[1]赵 倩,颜志平.载药微球经导管动脉化疗栓塞治疗肝癌研究进展 [J].介入放射学杂志,2017,(11):1052-1056.
　ZHAO Qian,YAN Zhiping.Transarterial chemoembolization with drug- eluting beads for the treatment of hepatocellular carcinoma： recent progress in research[J].journal interventional radiology,2017,(11):1052-1056.
点击复制

载药微球经导管动脉化疗栓塞治疗肝癌研究进展


()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2017年11期
页码:
1052-1056
栏目:
综述
出版日期:
2017-11-25

文章信息/Info

Title:
Transarterial chemoembolization with drug- eluting beads for the treatment of hepatocellular carcinoma： recent progress in research
作者:
赵 倩;  颜志平
Author(s):
ZHAO Qian;  YAN Zhiping
Department of Interventional Radiology， Affiliated Zhongshan Hospital， Fudan University， Shanghai Institute of Medical Imaging， Shanghai 200032， China
关键词:
【关键词】 肝细胞肝癌;  经导管动脉化疗栓塞术;  载药微球
文献标志码:
A
摘要:
【摘要】 肝细胞肝癌是肝脏最常见原发性恶性肿瘤，经导管动脉化疗栓塞术（TACE）是外科手术不能切除中晚期肝癌首选的有效治疗方法。载药微球TACE术是一种新兴治疗方式，能够持续缓慢释放化疗药物，提高药物局部浓度，降低全身血药浓度。在超选择基础上，直径＞100 μm载药微球TACE术安全有效，在肿瘤缓解率、减少手术次数、减少不良反应、缩短住院时间、提高生活质量等方面均较传统TACE术具有优势，对中期、Child- Pugh B级、体能活动状况1级、有两叶病变、复发性疾病患者治疗效果较好。但价格昂贵及当地医疗条件、医务人员能力、医保政策等限制了载药微球临床应用。载药微球TACE 治疗肝癌临床效果，有待进一步研究证实。

参考文献/References:

［1］ Forner A， Llovet JM， Bruix J. Hepatocellular carcinoma［J］. Lancet， 2012， 379： 1245- 1255.
［2］ Ferlay J， Shin HR， Bray F， et al. Estimates of worldwide burden of cancer in 2008： GLOBOCAN 2008［J］. Int J Cancer， 2010， 127： 2893- 2917.
［3］ Bruix J， Sherman M. Management of hepatocellular carcinoma［J］. Hepatology， 2005， 42： 1208- 1236.
［4］ Forner A， Reig ME， de Lope CR， et al. Current strategy for staging and treatment： the BCLC update and future prospects［J］. Semin Liver Dis， 2010， 30： 61- 74.
［5］ Poon TP， Tso WK， Pang RW， et al. A phase Ⅰ/Ⅱ trial of chemoembolization for hepatocellular carcinoma using a novel intra- arterial drug- eluting bead［J］. Clin Gastroenterol Hepatol， 2007， 5： 1100- 1108.
［6］ Varela M， Real MI， Burrel M， et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads： efficacy and doxorubicin pharmacokinetics［J］. J Hepatol， 2007， 46： 474- 481.
［7］ Hong K， Khwaja A， Liapi E， et al. New intra- arterial drug delivery system for the treatment of liver cancer： preclinical assessment in a rabbit model of liver cancer［J］. Clin Cancer Res， 2006， 12： 2563- 2567.
［8］ Fuchs K， Bize PE， Dormond O， et al. Drug- eluting beads loaded with antiangiogenic agents for chemoembolization： in vitro sunitinib loading and release and in vivo pharmacokinetics in an animal model［J］. J Vasc Interv Radiol， 2014， 25： 379- 387.
［9］ Vogl TJ， Lammer J， Lencioni R， et al. Liver， gastrointestinal， and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug- eluting beads： results from the PRECISION Ⅴ randomized trial［J］. AJR Am J Roentgenol， 2011， 197： W562- W570.
［10］ Lammer J， Malagari K， Vogl T， et al. Prospective randomized study of doxorubicin- eluting- bead embolization in the treatment of hepatocellular carcinoma： results of the PRECISIONⅤstudy［J］. Cardiovasc Intervent Radiol， 2010， 33： 41- 52.
［11］ Padia A， Shivaram G， Bastawrous S， et al. Safety and efficacy of drug- eluting bead chemoembolization for hepatocellular carcinoma： comparison of small- versus medium- size particles［J］. J Vasc Interv Radiol， 2013， 24： 301- 306.
［12］ Namur J， Wassef M， Millot JM， et al. Drug- eluting beads for liver embolization： concentration of doxorubicin in tissue and in beads in a pig model［J］. J Vasc Interv Radiol， 2010， 21： 259- 267.
［13］ Lee KH， Liapi E， Vossen JA， et al. Distribution of iron oxide- containing embosphere particles after transcatheter arterial embolization in an animal model of liver cancer： evaluation with MR imaging and implication for therapy［J］. J Vasc Interv Radiol， 2008， 19： 1490- 1496.
［14］ Gholamrezanezhad A， Mirpour S， Geschwind JH， et al. Evaluation of 70- 150- μm doxorubicin- eluting beads for transcatheter arterial chemoembolization in the rabbit liver VX2 tumour model［J］. Eur Radiol， 2016， 26： 3474- 3482.
［15］ Deipolyi AR， Oklu R， Al- Ansari S， et al. Safety and efficacy of 70- 150 μm and 100- 300 μm drug- eluting bead transarterial chemoembolization for hepatocellular carcinoma［J］. J Vasc Interv Radiol， 2015， 26： 516- 522.
［16］ Malagari K， Pomoni M， Moschouris H， et al. Chemoembolization of hepatocellular carcinoma with HepaSphere 30- 60 μm. Safety and efficacy study［J］. Cardiovasc Intervent Radiol， 2014， 37： 165- 175.
［17］ Frenette CT， Osorio RC， Stark J， et al. Conventional TACE and drug- eluting bead TACE as locoregional therapy before orthotopic liver transplantation［J］. Transplantation， 2014， 98： 781- 787.
［18］ Green TJ， Rochon PJ， Chang S， et al. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria： strategies using drug- eluting bead chemoembolization［J］. J Vasc Interv Radiol， 2013， 24： 1613- 1622.
［19］ Song MJ， Chun HJ， Song DS， et al. Comparative study between doxorubicin- eluting beads and conventional transarterial chemo- embolization for treatment of hepatocellular carcinoma［J］. J Hepatol， 2012， 57： 1244- 1250.
［20］ Liu YS， Ou MC， Tsai YS， et al. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol- doxorubicin versus doxorubicin- loaded beads for the treatment of hepatocellular carcinoma［J］. Korean J Radiol， 2015， 16： 125- 132.
［21］ Dhanasekaran R， Kooby DA， Staley CA， et al. Comparison of conventional transarterial chemoembolization（TACE） and chemoembolization with doxorubicin drug eluting beads （DEB） for unresectable hepatocelluar carcinoma（HCC）［J］. J Surg Oncol， 2010， 101： 476- 480.
［22］ Wiggermann P， Sieron D， Brosche C， et al. Transarterial chemoembolization of Child- A hepatocellular carcinoma： drug- eluting bead TACE（DEB TACE） vs. TACE with cisplatin/lipiodol （cTACE）［J］. Med Sci Monit， 2011， 17： CR189- CR195.
［23］ Golfieri R， Giampalma E， Renzulli M， et al. Randomised controlled trial of doxorubicin- eluting beads vs conventional chemoembolisation for hepatocellular carcinoma［J］. Br J Cancer， 2014， 111： 255- 264.
［24］ Sacco R， Bargellini I， Bertini M， et al. Conventional versus doxorubicin- eluting bead transarterial chemoembolization for hepatocellular carcinoma［J］. J Vasc Interv Radiol， 2011， 22： 1545- 1552.
［25］ Kloeckner R， Weinmann A， Prinz F， et al. Conventional transarterial chemoembolization versus drug- eluting bead transar- terial chemoembolization for the treatment of hepatocellular carcinoma［J］. BMC Cancer， 2015， 15： 465.
［26］ Facciorusso A， Di Maso M， Muscatiello N. Drug- eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma： a meta- analysis［J］. Dig Liver Dis， 2016， 48： 571- 577.
［27］ 周官辉， 孙军辉， 张岳林， 等． HepaSphere载药微球栓塞治疗不可切除肝癌15例［J］． 介入放射学杂志， 2015， 24： 869- 872．
［28］ 罗剑钧， 颜志平， 王建华， 等． 微球+碘化油联合栓塞与碘化油单独栓塞治疗肝癌的比较研究［J］． 中国医学计算机成像杂志， 2008， 14： 154- 159．
［29］ Huang K， Zhou Q， Wang R， et al. Doxorubicin- eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma［J］. J Gastroenterol Hepatol， 2014， 29： 920- 925.
［30］ Xing M， Webber G， Prajapati HJ， et al. Preservation of quality of life with doxorubicin drug- eluting bead transarterial chemoembo- lization for unresectable hepatocellular carcinoma： longitudinal prospective study［J］. J Gastroenterol Hepatol， 2015， 30： 1167- 1174.
［31］ Cucchetti A， Trevisani F， Cappelli A， et al. Cost- effectiveness of doxorubicin- eluting beads versus conventional trans- arterial chemo- embolization for hepatocellular carcinoma［J］. Dig Liver Dis， 2016， 48： 798- 805.
［32］ Hoffmann R， Rempp H， Syha R， et al. Transarterial chemoem- bolization using drug eluting beads and subsequent percutaneous MR- guided radiofrequency ablation in the therapy of intermediate sized hepatocellular carcinoma［J］. Eur J Radiol， 2014， 83： 1793- 1798.
［33］ Cosgrove DP， Reyes DK， Pawlik TM， et al. Open- label single- arm phase Ⅱ trial of sorafenib therapy with drug- eluting bead transarterial chemoembolization in patients with unresectable hepatocellular carcinoma： clinical results［J］. Radiology， 2015， 277： 594- 603.
［34］ Martin RC， Joshi J， Robbins K， et al. Hepatic intra- arterial injection of drug- eluting bead， irinotecan（DEBIRI） in unresectable colorectal liver metastases refractory to systemic chemotherapy： results of multi- institutional study［J］. Ann Surg Oncol， 2011， 18： 192- 198.
［35］ Bower M， Metzger T， Robbins K， et al. Surgical downstaging and neo- adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug- eluting beads： a multi- institutional study［J］. HPB（Oxford）， 2010， 12： 31- 36.
［36］ Bhutiani N， Akinwande O， Martin RC 2nd. Efficacy and toxicity of hepatic intra- arterial drug- eluting（irinotecan） bead （DEBIRI） therapy in irinotecan- refractory unresectable colorectal liver metastases［J］. World J Surg， 2016， 40： 1178- 1190.
［37］ Fiorentini G， Aliberti C， Tilli M， et al. Intra- arterial infusion of irinotecan- loaded drug- eluting beads（DEBIRI） versus intravenous therapy（FOLFIRI） for hepatic metastases from colorectal cancer： final results of a phase Ⅲ study［J］. Anticancer Res， 2012， 32： 1387- 1395.

相似文献/References:

[1]王惠文,刘瑞宝,刘　　　岩,等.原发性肝癌ＴＡＣＥ后ＦＡＫ、ＮＦκＢｐ６５表达及意义[J].介入放射学杂志,2011,(08):621.
　WANG Hui-wen,LIU Rui-bao,LIU Yan,et al.The expression and significance of FAK and NF-κBp65 in hepatocellular carcinoma after transcatheter arterial chemoembolization[J].journal interventional radiology,2011,(11):621.
[2]赵 艳,韩国宏,白 苇,等. 药物缓释微球肝动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志,2012,(01):78.
　ZHAO Yan,HAN Guo-hong,BAI Wei,et al.Transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma: its research progress[J].journal interventional radiology,2012,(11):78.
[3]杨柏帅,施裕新,袁 敏,等.TACE治疗既往有肝功能衰竭史肝癌患者七例[J].介入放射学杂志,2014,(09):805.
　YANG Bo shuai,SHI Yu xin,YUAN Min,et al.TACE treatment for patients with inoperable hepatocellular carcinoma and hepatic failure history： initial experience in seven cases[J].journal interventional radiology,2014,(11):805.
[4]王以浪,王亚非,张 亮,等. 肝细胞癌患者TACE术前后血清miR- 21表达变化及临床意义[J].介入放射学杂志,2014,(05):406.
　WANG Yi- lang,WANG Ya- fei,ZHANG Liang,et al. The changes of serum miR- 21 expression level in patients with HCC before and after TACE and its clinical significance[J].journal interventional radiology,2014,(11):406.
[5]邢桃红,牛焕章,周媛媛,等. TACE联合索拉非尼治疗23例中晚期肝细胞肝癌的护理[J].介入放射学杂志,2014,(05):449.
　XING Tao- hong,NIU Huan- zhang,ZHOU Yuan- yuan,et al. Nursing for patients with advanced hepatocellular carcinoma receiving transcatheter arterial chemoembolization combined with sorafenib： initial experience in 23 cases[J].journal interventional radiology,2014,(11):449.
[6]阿布都外力·吾布力卡斯穆,迪里木拉提·巴吾冬,任伟新. 巴塞罗那肝癌B期患者TACE治疗的预后及生存分析[J].介入放射学杂志,2014,(05):435.
　ABUDUWAILI Obulikasimu,DILMURAT Bawudun,REN Wei- xin.. Transcatheter arterial chemoembolization for the treatment of Barcelona stage B hepatocellular carcinoma： analysis of the prognosis and survival[J].journal interventional radiology,2014,(11):435.
[7]尹芝兰,肖恩华.原发性肝癌行TACE术后对乙型肝炎病毒影响[J].介入放射学杂志,2014,(12):1114.
　YIN Zhi lan,XIAO En hua..The influence of TACE for primary hepatocellular carcinoma on hepatitis B virus[J].journal interventional radiology,2014,(11):1114.
[8]王 龙,张 勇,王亚运,等.125I粒子联合经导管动脉化疗栓塞治疗肝细胞肝癌伴门静脉癌栓临床有效性与安全性meta 分析[J].介入放射学杂志,2018,27(05):419.
　WANG Long,ZHANG Yong,WANG Yayun,et al.125I seed implantation combined with TACE for the treatment of HCC complicated by portal vein tumor thrombus： a meta- analysis of its clinical effectiveness and safety[J].journal interventional radiology,2018,27(11):419.
[9]李 征,米登海,杨克虎,等.经动脉化疗栓塞联合微波消融治疗肝癌有效性和安全性的系统评价[J].介入放射学杂志,2015,(11):957.
　LI Zheng,MI Deng- hai,YANG Ke- hu,et al.Effectiveness and safety of TACE combined with MWA for primary hepatic cancer： a systematic review[J].journal interventional radiology,2015,(11):957.
[10]许 贇,沈 强,王 能,等.微波消融治疗＞70岁早期肝细胞肝癌患者效果分析[J].介入放射学杂志,2016,(04):332.
　XU Yun,SHEN Qiang,WANG Neng,et al.Effect analysis of microwave ablation therapy for early hepatocellular carcinoma in patients over 70 years old[J].journal interventional radiology,2016,(11):332.
[11]杨柏帅,施裕新,袁 敏,等.终末期肾衰竭肝癌患者TACE术中应用洛铂治疗3例[J].介入放射学杂志,2016,(05):381.
　YANG Bo- shuai,SHI Yu- xin,YUAN Min,et al.Transcatheter arterial chemoembolization using lobaplatin and lipiodol for the treatment of hepatocellular carcinoma associated with end- stage renal failure： report of three cases[J].journal interventional radiology,2016,(11):381.
[12]余晨曦,滕皋军.经导管动脉化疗栓塞术抵抗研究进展 [J].介入放射学杂志,2017,(12):1063.
　YU Chenxi,TENG Gaojun.Transarterial chemoembolization refractory： current research progress[J].journal interventional radiology,2017,(11):1063.
[13]徐 圣,张学军,石宝琪,等.微波消融联合经导管动脉化疗栓塞术治疗肝细胞癌生存预测[J].介入放射学杂志,2020,29(05):508.
　XU Sheng,ZHANG Xuejun,SHI Baoqi,et al.The survival prediction for HCC patients receiving microwave ablation combined with TACE[J].journal interventional radiology,2020,29(11):508.
[14]荆 霞,徐 圣.Callispheres栓塞后综合征的综合护理模式与常规护理模式比较[J].介入放射学杂志,2020,29(07):722.
　JING Xia,XU Sheng..Comprehensive nursing mode versus routine nursing mode for post- embolization syndrome in HCC patients after DEB- TACE： a comparative study[J].journal interventional radiology,2020,29(11):722.
[15]沈建东,戴 锋,王 斌,等.磷脂酰肌醇-4，5-二磷酸肌醇-3-激酶对原发性肝癌TACE治疗反应的预测作用[J].介入放射学杂志,2024,33(04):382.
　SHEN Jiandong,DAI Feng,WANG Bin,et al.The application of PIK3CA in predicting the efficacy of TACE in the treatment of primary liver cancer[J].journal interventional radiology,2024,33(11):382.

备注/Memo

备注/Memo:
（收稿日期：２０１6-1０-０8）
（本文编辑：边 佶）
更新日期/Last Update: 2017-11-16